A rapidly changing psychiatric presentation and a positive serum IgG anti-GluN1 test can pull reasoning in opposite directions: dismiss encephalitis as psychiatric, or diagnose encephalitis from an assay alone. The useful distinction is mechanistic: anti-NMDA receptor encephalitis is best understood as antibody-driven loss of functional surface receptors, not simply a channel with a plug in its pore. The clinical question is how that mechanism should shape assessment of an evolving psychiatric syndrome and the threshold for neurologic work-up.
What the antibodies do at the synapse
Normal NMDA receptor function depends on activity at the synapse. In anti-NMDA receptor encephalitis, IgG antibodies target extracellular, conformational sites on the GluN1 subunit, formerly called NR1. They bind and cross-link surface receptors, promoting receptor clustering and internalization. The result is fewer functional receptors available at the synapse and reduced NMDA-mediated currents.
That is different from simply blocking the channel pore. In experimental neuronal models, antibody-driven internalization—not evidence of acute direct pore blockade—best explains the reduction in receptor function. Surface receptor levels can recover after antibodies are removed from these cultures, supporting a potentially reversible synaptic disturbance; that experimental finding does not guarantee an individual patient’s recovery or establish that tissue injury never occurs.
The circuit effect is not a simple equation in which “less NMDA” means uniformly less brain activity. NMDA receptors occur on excitatory and inhibitory neurons, and receptor loss can prompt further changes in synaptic networks. The mechanism makes altered cognition and behavior biologically plausible, but it does not map a particular delusion, hallucination, or mood symptom to one receptor change.
Keep mechanism, syndrome, and test separate
| Level | What it supports | What it does not establish |
|---|---|---|
| Synaptic mechanism | Antibody-related loss of surface GluN1-containing receptors and reduced NMDA signaling | A one-to-one explanation for a specific psychiatric symptom, or simple pore blockade as the whole mechanism |
| Clinical presentation | A rapidly evolving combination of psychiatric, cognitive, speech, movement, seizure, consciousness, or autonomic changes raises concern for encephalitis | Anti-NMDA receptor encephalitis from psychosis alone; primary psychiatric disorders remain an important differential |
| Antibody result | A compatible clinical syndrome plus appropriately interpreted IgG anti-GluN1 testing can support the diagnosis | Encephalitis from an isolated serum result without clinical and laboratory context |
A plausible receptor mechanism is not itself a diagnosis. Psychiatric symptoms may occur early in anti-NMDA receptor encephalitis, but they are not specific to it. The more useful discriminator is often the course: rapid progression or fluctuation, especially when cognitive or neurologic features join the psychiatric symptoms.
Let the trajectory change your assessment
Establish the patient’s cognitive, psychiatric, and functional baseline, then build a timeline of what changed and how quickly. Ask about new memory problems, reduced or unusual speech, seizures, abnormal movements or postures, catatonic features, fluctuating alertness, autonomic instability, and hypoventilation. With the patient’s agreement, collateral can help distinguish a major departure from baseline from a long-standing pattern. Review medications, substances, and other medical causes rather than assuming that a psychiatric history rules out encephalitis—or that no such history proves it.
Catatonia, agitation, and psychosis can occur in several conditions; none alone identifies the cause. But if a psychiatric presentation progresses over days or weeks and new neurologic or autonomic signs emerge, the assessment should broaden from “which primary psychiatric syndrome fits?” to “could this be an acute or subacute encephalopathy?” That change calls for urgent medical and neurologic evaluation, not simply a change in psychiatric labeling.
For board reasoning, probable anti-NMDA receptor encephalitis criteria require rapid onset—within less than three months—of at least four of six symptom groups: psychiatric or cognitive dysfunction, speech dysfunction, seizures, movement disorder or abnormal postures, decreased level of consciousness, and autonomic dysfunction or central hypoventilation. Three groups may suffice when a systemic teratoma is present. The criteria also require at least one specified laboratory finding—an abnormal EEG (focal or diffuse slowing or disorganized activity, epileptic activity, or extreme delta brush), or CSF pleocytosis or oligoclonal bands—and reasonable exclusion of other disorders. Definite criteria require at least one symptom group and IgG anti-GluN1 antibodies, after reasonable exclusion of alternatives. Antibody testing should include CSF; if only serum is available, confirmatory testing beyond a cell-based assay is recommended. These criteria help classify a syndrome; they are not a reason to wait for every feature to appear before seeking evaluation.
When the course warrants it, coordinate medical and neurology assessment, EEG, brain MRI, and lumbar puncture with evaluation for infection and other causes. Include CSF IgG anti-GluN1 testing; paired serum can add context, but a serum-only result should be interpreted in light of the assay and clinical picture, and requires confirmatory testing if used to meet definite criteria. In a paired-sample study of established cases, CSF testing was more sensitive than serum testing using the study’s combined assay approach. A normal MRI does not rule out the disease, and no nonspecific EEG, CSF, or blood finding establishes it by itself.
This is a calibration problem in both directions. Indiscriminate antibody screening in chronic, stable psychiatric illness can produce misleading results when the pretest probability is low. Conversely, waiting for the complete textbook sequence can delay recognition when a rapidly progressive syndrome is accumulating features. Psychiatric symptom management and safety planning can continue while the medical evaluation proceeds.
Practical takeaways
- Anti-GluN1 IgG primarily reduces surface receptor availability through cross-linking and internalization; think receptor loss, not just pore blockade.
- NMDA receptor hypofunction offers a mechanism, not a specific psychiatric diagnosis or a one-symptom explanation.
- Establish baseline and timeline. Rapid progression with new speech, cognitive, seizure, movement, consciousness, or autonomic changes warrants urgent neurologic assessment.
- Interpret antibody results in context. CSF testing matters, serum alone is not a diagnosis, and a normal MRI does not exclude encephalitis.
